Page 13 - Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Retrospective analysis of patients with myelodysplastic syndromes showed trends in treatment patterns that suggest: improved trend persistence with oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents beyond 6 months comparable persistence between oral decitabine and cedazuridine and intravenous/subcutaneous hypomethylating agents at early stages of therapy PRINCETON, N.J., Dec. 10, 2023 /PRNewswire/ — Taiho Oncology, Inc. announced […]

11.12.2023 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve ... Seite 1

EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome…

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.